Breaking the time capsule: Life Sciences in 2010 and today
CRA’s Life Sciences Practice team recently analyzed past predictions of industry trends and compared them to what has occurred in the past decade, identified...
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
We are rare disease specialists.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
- 50+Rare disease areas covered
- 600+Rare disease engagements since 2017
Our rare disease offerings span across the product lifecycle.
- Early developmentDiscover
- Early PMA assessment
- Pipeline opportunity assessment
- Diagnostics & screening
- Incentives review
- Licensing / commercially reasonable efforts disputes
- Late developmentDevelop
- Market access & evidence generation strategy
- Payer value proposition
- Patient finding
- Landscape assessment & policy shaping
- LaunchDeliver
- Launch pricing strategy
- Payer negotiation
- Launch excellence
- Stakeholder engagement
- Competitive simulations
- Regulatory and P&R policies
- Uptake and diffusion
- Life cycle & LOEDefend
- Indication & geographic expansion
- Competitor response strategies
- Price/access/uptake benchmarking and assessments
- LOE strategies
Healthcare Claims Analytics Platform (HCAP)
Healthcare Claims Analytics Platform (HCAP) is a modular, dynamic, rapidly updating data-visualization tool that provides streamlined analysis of patient, Health Care Practitioner (HCP), and Health Care Organization (HCO) level data to support decision making and insight generation. HCAP supports clients in visualizing advanced analytics to provide intelligence on patients, physicians, hospitals, and the broader healthcare market. With the information obtained from HCAP, clients are better informed to make key strategic decisions.
Engagements
- 01Evaluating the potential impact of cross-border healthcare for gene therapiesIssue Our client sought to understand the current state of healthcare across borders (also known as medical tourism) and the opportunities and risks this...View engagement
- 02Global pricing and access strategic issues assessment for rare diseases gene therapy portfolioIssue Our client is developing gene therapies for different rare disease indications, some with effective treatments available and others with only symptom...View engagement
- 03Understanding and segmenting a rare disease marketClient Issue Our client sought to develop a better understanding of the market for a rare disease, including patient diversity and treatment, in anticipation...View engagement
Meet our team
Recent and Upcoming Events
Time to act: Building a pharmaceutical framework fit for rare diseases
Milan Ferguson presents during the panel session titled ” The value of newborn screening: An SMA case study.” For more information on this event, click here.
World Orphan Drug Congress Europe 2022
CRA is a proud sponsor of the congress. Cecile Matthews and Bhavesh Patel present their session titled “Project LEOPARD (Long-term Evolution & Outlook for...